Gilead CAR-T deal with Aus biotech oNKo-innate., page-2

Interesting space CAR-T , PTX has collaboration with Carina Biotech who is developing CAR-T for targeting solid tumours. Carina Biotech expecting to trial on humans in 2020. Considering the size of deals done in the CAR-T market a collaboration resulting in shared IP could add substantial value to PTX. http://carinabiotech.com/


Dec 10, 2019
https://kalkinemedia.com/au/healthcare/prescient-collaborates-with-carina-biotech-in-expansion-into-exciting-car-t-therapies

Another company that is operating in similar CAR-T medicine space is Juno Therapeutics which was acquired by Celgene in a US$9 B deal in January 2018. Recently, Bristol-Myers Squibb completed a US$74 B acquisition of Celgene in November 2019.

Prescient’s Collaboration with Carina Biotech Addresses the Current Challenges of CAR-T Technologies

This collaboration will bring together Prescient’s expertise in targeted therapies with Carina Biotech’s promising cell therapies to improve CAR-T approaches to treat an array of cancers, in turn, offering a vast area of opportunity while seeking to address some of the current challenges of CAR-T therapy. No additional capital would be required to carry out the work as it would be undertaken within Prescient’s existing budget. While the exact terms and conditions of the agreement and collaboration remain confidential, any consequential IP arising from this alliance would be shared by both Prescient and Carina.